目的　探讨血清可溶性白细胞介素２ 受体（ｓ Ｉ Ｌ２ Ｒ）水平与恶性肿瘤患者的病期及疗效的关系。方法　采用双抗体夹心 Ｅ Ｌ Ｉ Ｓ Ａ 法检测１５９ 例恶性肿瘤患者放疗前后血清ｓ Ｉ Ｌ２ Ｒ 水平。结果　恶性肿瘤患者放疗前血清ｓ Ｉ Ｌ２ Ｒ 水平明显高于正常对照组（ Ｐ＜ ００５）；放疗后血清ｓ Ｉ Ｌ２ Ｒ 水平明显低于放疗前（ Ｐ ＜ ０００１）；晚期患者（Ⅲ＋ Ⅳ期）不论是放疗前或放疗后 ｓ Ｉ Ｌ２ Ｒ 水平均明显高于早期患者（Ⅰ＋ Ⅱ期）（ Ｐ ＜ ００５）；各类恶性肿瘤之间血清ｓ Ｉ Ｌ２ Ｒ 水平无显著性差异（ Ｐ ＞００５）。结论　ｓ Ｉ Ｌ２ Ｒ水平在各种恶性肿瘤中的表达无特异性；检测恶性肿瘤患者ｓ Ｉ Ｌ２ Ｒ 放疗前后水平，是对病情估计和治疗疗效评价的一项参考指标。 Objective To investigate the relationship between serum soluble interleukin2 receptor (sIL2R) level and the duration and efficacy of malignant tumor patients. Methods Serum IL-2R levels in 159 patients with malignant tumor before and after radiotherapy were detected by double antibody sandwich ELISA. Results Before treatment, the level of serum sIR2R in patients with malignant tumor was significantly higher than that in the normal control group (P <005). The level of serum sIRR after radiotherapy was significantly lower than that before radiotherapy (P0001) ; In advanced stage (stage Ⅲ + Ⅳ), the levels of s IR2R were significantly higher than those in early stage (stage Ⅰ + Ⅱ) before or after radiotherapy (P0.05); serum s Ⅰ L  2 R level no significant difference (P> 0  05). Conclusion The expression level of s I L2 R in various malignancies is nonspecific. To detect the levels of s I L2 R before and after radiotherapy in patients with malignant tumors is a reference index for assessing the disease status and evaluating the curative effect.